Blog
Announcing IPC’s New Leadership for 2025.
Welcome the newest leadership to the IPC Board of Directors! Meet incoming IPC President Bruce Strober, Vice…
Welcome the newest leadership to the IPC Board of Directors! Meet incoming IPC President Bruce Strober, Vice…
Read MoreINTERNATIONAL FEDERATION OF PSORIASIS ASSOCIATION CONFERENCE (IFPA) | STOCKHOLM, SWEDEN Friday, June 28 17:45 - 18:45…
Generalized pustular psoriasis(GPP)lacks internationally accepted definitions and diagnostic criteria, impeding timely…
View ReportJoin Dr. Claudia de la Cruz, a dermatologist from Santiago, Chile, and Secretary of the International Psoriasis…
Read MoreIPC stands for accessible treatment and universal healthcare on World Psoriasis Day and beyond. Gain insights from…
Read MoreDiscover the latest updates on psoriasis from the World Congress of Dermatology (WCD) 2023, hosted in Singapore from…
Read MoreDiscover the latest updates on psoriasis from the World Congress of Dermatology (WCD) 2023, hosted in Singapore from…
View ReportDr. Claudia de la Cruz discusses the recent advances in the management of scalp psoriasis. La Dra. Claudia de la…
Watch VideoThe patient perspective has become even more important in the wake of the pandemic. Here’s how Clinica Dermacross is…
Read MoreREUNIÓN ANUAL DE DERMATÓLOGOS LATINOAMERICANOS (RADLA) | CURITIBA, BRAZIL Friday, May 26 14:00 – 17:00 BRT 13:00…
El Dra. de la Cruz analiza por qué es importante que los médicos vean la psoriasis desde la perspectiva del paciente…
Watch VideoDr. de la Cruz discusses why it’s important for physicians to view psoriasis from the patient’s perspective and how…
Watch VideoWORLD CONGRESS OF DERMATOLOGY (WCD) | SINGAPORE Monday, July 3 14:30 - 17:30 SGT Program chairs: Claudia de la…
La XXXIX Reunión Anual de Dermatólogos Latinoamericanos (RADLA) se realizó de manera virtual del 2 al 5 de mayo,…
Read MoreThe 4th webinar in the series will center around the organization of psoriasis clinics now and in the future, including…
Watch VideoIPC's newly appointed appointed officers take their roles beginning January 1, 2022.
Read MoreBiologics and biosimilars have created many new options in psoriasis treatment for patients worldwide, but patients…
Read MoreView Report
The introduction of biological drugs for the treatment of patients with psoriasis has revolutionized treatment…
View Report| Cookie | Duration | Description |
|---|---|---|
| cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
| cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
| cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
| cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
| cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
| viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
IPC Councilor Helen Young provides commentary on a study identifying skin-derived myeloid precursors and CD200+ fibroblasts as key drivers of psoriatic disease spread from the skin to joints, highlighting the CD200–CD200R1 axis as a promising therapeutic target.
IPC Fellow Dr. Yemsrach Abawaji shares her firsthand perspective on the barriers to psoriasis diagnosis and treatment in Ethiopia and opportunities to improve care.
Did you miss the IPC symposium at the 83rd Society for Investigative Dermatology (SID) Annual Meeting? Select session videos are now available. The Arc of Disease Control in Psoriasis: Early Interception – Deep Pathway Blockade – Treatment Failure covered early intervention strategies, treatment selection, immune pathway targeting, PsA prevention, clinical escape, and real-world cases that inform long-term psoriasis care.
Depression affects approximately 20% of patients with psoriasis, five times the rate seen in the general population. IPC Jr. Councilor Mio Nakamura, MD, MS, FAAD, walks through the bidirectional relationship between psoriasis and depression, the shared inflammatory pathways driving both conditions, and practical guidance on screening and incorporating multidisciplinary mental health support into psoriasis management.